Q1 Earnings Estimate for Entera Bio Issued By HC Wainwright

Key Points

• HC Wainwright has projected Entera Bio's Q1 2026 earnings per share to be at ($0.15), maintaining a "Strong-Buy" rating for the stock.
• Entera Bio reported ($0.06) earnings per share in their most recent quarter, exceeding the consensus estimate of ($0.11) by $0.05.
• The stock is currently priced at $1.91, with a market cap of $86.86 million and a fifty-two week trading range between $1.50 and $2.79.

Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Entera Bio in a research report issued to clients and investors on Monday, August 11th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright has a "Strong-Buy" rating on the stock. The consensus estimate for Entera Bio's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Entera Bio's Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.67) EPS.

Entera Bio (NASDAQ:ENTX - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.05. Entera Bio had a negative return on equity of 77.75% and a negative net margin of 4,525.11%.

Entera Bio Stock Up 1.1%

NASDAQ ENTX opened at $1.91 on Wednesday. Entera Bio has a fifty-two week low of $1.50 and a fifty-two week high of $2.79. The stock has a market cap of $86.86 million, a price-to-earnings ratio of -7.35 and a beta of 1.52. The business has a fifty day moving average of $1.95 and a 200-day moving average of $2.00.

Hedge Funds Weigh In On Entera Bio

Institutional investors have recently made changes to their positions in the stock. Northern Trust Corp acquired a new position in shares of Entera Bio in the fourth quarter worth $450,000. Knoll Capital Management LLC increased its stake in Entera Bio by 51.5% in the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after purchasing an additional 2,000,000 shares during the last quarter. Bessemer Group Inc. acquired a new position in Entera Bio in the second quarter valued at $268,000. Parkman Healthcare Partners LLC increased its stake in Entera Bio by 6.3% in the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock valued at $747,000 after purchasing an additional 25,900 shares during the last quarter. Finally, HighTower Advisors LLC increased its stake in Entera Bio by 53.3% in the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock valued at $31,000 after purchasing an additional 6,310 shares during the last quarter. 14.11% of the stock is owned by institutional investors and hedge funds.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.